Amedisys (AMED) Competitors

DaVita (NYSE:DVA) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Which has more risk and volatility, DVA or AMED?

DaVita has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.

Do analysts prefer DVA or AMED?

DaVita currently has a consensus price target of $169.33, suggesting a potential upside of 32.70%. Amedisys has a consensus price target of $100.50, suggesting a potential downside of 0.38%. Given DaVita's higher possible upside, research analysts plainly believe DaVita is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amedisys	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals & insiders have more ownership in DVA or AMED?

90.1% of DaVita shares are held by institutional investors. Comparatively, 94.4% of Amedisys shares are held by institutional investors. 2.0% of DaVita shares are held by company insiders. Comparatively, 2.1% of Amedisys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media refer more to DVA or AMED?

In the previous week, DaVita had 16 more articles in the media than Amedisys. MarketBeat recorded 29 mentions for DaVita and 13 mentions for Amedisys. Amedisys' average media sentiment score of 0.96 beat DaVita's score of 0.59 indicating that Amedisys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	12 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amedisys	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has higher earnings & valuation, DVA or AMED?

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$12.82B	0.71	$936.34M	$10.17	12.55
Amedisys	$2.35B	1.41	$43.23M	$2.57	39.25

Is DVA or AMED more profitable?

DaVita has a net margin of 6.35% compared to Amedisys' net margin of 3.56%. DaVita's return on equity of 369.39% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.35%	369.39%	4.62%
Amedisys	3.56%	12.91%	7.29%

Summary

DaVita and Amedisys tied by winning 8 of the 16 factors compared between the two stocks.